Last reviewed · How we verify
Candida Antigen
Candida Antigen is a diagnostic skin test antigen derived from Candida albicans that elicits a delayed-type hypersensitivity reaction to assess cell-mediated immune function.
Candida Antigen is a diagnostic skin test antigen derived from Candida albicans that elicits a delayed-type hypersensitivity reaction to assess cell-mediated immune function. Used for Assessment of cell-mediated immunity and immunocompetence in immunocompromised patients, Evaluation of delayed-type hypersensitivity response.
At a glance
| Generic name | Candida Antigen |
|---|---|
| Also known as | Candin |
| Sponsor | University of Arkansas |
| Drug class | Diagnostic antigen / Immunological test |
| Modality | Small molecule |
| Therapeutic area | Immunology / Diagnostics |
| Phase | FDA-approved |
Mechanism of action
The antigen is injected intradermally, and a positive reaction (induration at the injection site) indicates intact T-cell mediated immunity. It is used clinically as an immunocompetence test to evaluate whether a patient's immune system can mount a normal delayed hypersensitivity response, helping to assess immunosuppression or immune deficiency.
Approved indications
- Assessment of cell-mediated immunity and immunocompetence in immunocompromised patients
- Evaluation of delayed-type hypersensitivity response
Common side effects
- Local induration or erythema at injection site
- Systemic hypersensitivity reactions
Key clinical trials
- Non-Conventional Microbiological Methods in the Diagnosis of Candidemia (NA)
- Combination Therapy for Warts: Candida Antigen vs. Topical Keratolytic (PHASE2)
- Staging Candidiasis in ICU Patients
- Candin for the Treatment of Common Warts (PHASE3)
- Immunotherapy in Eyelid Viral Papilloma (PHASE2)
- Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis (NA)
- Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts (PHASE2)
- Immunologic Profile of Chronically Photodamaged Skin (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Candida Antigen CI brief — competitive landscape report
- Candida Antigen updates RSS · CI watch RSS
- University of Arkansas portfolio CI